<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404011</url>
  </required_header>
  <id_info>
    <org_study_id>Université Libre de Bruxelles</org_study_id>
    <nct_id>NCT03404011</nct_id>
  </id_info>
  <brief_title>Acute Effects of Propylene Glycol/Glycerol Intake on Blood Parameters</brief_title>
  <acronym>AEPGGIBP</acronym>
  <official_title>Acute Effects of Propylene Glycol/Glycerol Intake on Cardiorespiratory Blood Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Libre de Bruxelles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the acute effect of propylene glycol and glycerol intake
      on cardiorespiratory blood parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background : Propylene glycol/glycerol intake is increasingly popular. Acute effect of
      propylene glycol and glycerol intake on cardiorespiratory blood parameters is unknown. The
      investigators postulate that intake of propylene glycol and glycerol could modifiy
      cardiorespiratory blood parameters.

      Aims of this study : to test the following hypotheses :

      1) Acute intake of propylene glycol and glycerol modifies cardiorespiratory blood parameters.

      To test this hypothesis, we will perform blood samples before and after intake of propylene
      glycol and glycerol. Participants will be tobacco smoker between 18 and 70 years old, with
      multiple cardiovascular risk factors, and who will undergo a cardiac catherization. After the
      cardiac catherization, the catheter will be used to perform serial blood samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiorespiratory biological variables</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory biological variables</measure>
    <time_frame>20 minutes</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Complication</condition>
  <arm_group>
    <arm_group_label>Propylene glycol and Glycerol intake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One gram intake of a Propylene glycol/Glycerol mix (50:50)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mimicking intake</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Mimicking Propylene glycol/Glycerol intake with the device turns off</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propylene glycol and Glycerol intake</intervention_name>
    <description>Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.</description>
    <arm_group_label>Propylene glycol and Glycerol intake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mimicking intake</intervention_name>
    <description>Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.</description>
    <arm_group_label>Mimicking intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject undergoing cardiac catherization

          -  Subject must be an active tobacco smoker

        Exclusion Criteria:

          -  Symptoms of infection or inflammation

          -  Acute disease including heart rhythm disorder, acute coronary syndrome or
             decompensation of a chronic disease (heart failure, COPD,...)

          -  Unexpected and undesirable effects during the cardiac catherization procedure

          -  Respiratory failure requiring supplementary oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Chaumont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Libre de Bruxelles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint-Pierre Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Libre de Bruxelles</investigator_affiliation>
    <investigator_full_name>Martin Chaumont</investigator_full_name>
    <investigator_title>MD, Cardiology Fellow</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared upon reasonnable request</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03404011/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

